Cardlytics Inc. [NASDAQ: CDLX] closed the trading session at $4.51 on 11/02/22. The day’s price range saw the stock hit a low of $4.43, while the highest price level was $7.13. The company report on November 1, 2022 that Cardlytics Announces Third Quarter 2022 Financial Results.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
“We delivered solid double-digit growth despite the serious challenges present in the economy,” said Karim Temsamani, CEO of Cardlytics. “While the economy may be uncertain, I believe there is inherent resiliency in platforms that prove return on ad spend, and I am positive that we can grow profitably. There is a large opportunity ahead of us, and we will be disciplined in Q4 and beyond as we prioritize our goals and position the company well for the next ten years.”.
The stocks have a year to date performance of -93.18 percent and weekly performance of -50.44 percent. The stock has been moved at -88.20 percent over the last six months. The stock has performed -55.17 percent around the most recent 30 days and changed -69.40 percent over the most recent 3-months.
If compared to the average trading volume of 509.31K shares, CDLX reached to a volume of 4717421 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Cardlytics Inc. [CDLX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CDLX shares is $15.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CDLX stock is a recommendation set at 3.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Cardlytics Inc. shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on September 08, 2022. While these analysts kept the previous recommendation, Wells Fargo dropped their target price from $72 to $15. The new note on the price target was released on July 14, 2022, representing the official price target for Cardlytics Inc. stock. Previously, the target price had yet another raise to $14, while BofA Securities analysts kept a Underperform rating on CDLX stock. On July 12, 2022, analysts decreased their price target for CDLX shares from 50 to 20.
The Average True Range (ATR) for Cardlytics Inc. is set at 1.10, with the Price to Sales ratio for CDLX stock in the period of the last 12 months amounting to 0.47. The Price to Book ratio for the last quarter was 0.27, with the Price to Cash per share for the same quarter was set at 5.03.
CDLX stock trade performance evaluation
Cardlytics Inc. [CDLX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -50.44. With this latest performance, CDLX shares dropped by -55.17% in over the last four-week period, additionally sinking by -88.20% over the last 6 months – not to mention a drop of -94.34% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CDLX stock in for the last two-week period is set at 25.76, with the RSI for the last a single of trading hit 21.42, and the three-weeks RSI is set at 28.69 for Cardlytics Inc. [CDLX]. The present Moving Average for the last 50 days of trading for this stock 10.40, while it was recorded at 8.52 for the last single week of trading, and 31.14 for the last 200 days.
Cardlytics Inc. [CDLX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Cardlytics Inc. [CDLX] shares currently have an operating margin of -36.26 and a Gross Margin at +35.93. Cardlytics Inc.’s Net Margin is presently recorded at -48.13.
Return on Equity for this stock declined to -30.33, with Return on Assets sitting at -15.25.
Cardlytics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 0.90.
Earnings per share (EPS) analysis for Cardlytics Inc. [CDLX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CDLX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Cardlytics Inc. go to 25.30%.
Cardlytics Inc. [CDLX]: Insider Ownership positions
There are presently around $138 million, or 97.00% of CDLX stock, in the hands of institutional investors. The top three institutional holders of CDLX stocks are: CAS INVESTMENT PARTNERS, LLC with ownership of 5,416,116, which is approximately 0% of the company’s market cap and around 2.40% of the total institutional ownership; VANGUARD GROUP INC, holding 2,958,847 shares of the stock with an approximate value of $13.34 million in CDLX stocks shares; and BLACKROCK INC., currently with $11.83 million in CDLX stock with ownership of nearly 10.634% of the company’s market capitalization.
Positions in Cardlytics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 79 institutional holders increased their position in Cardlytics Inc. [NASDAQ:CDLX] by around 2,091,371 shares. Additionally, 75 investors decreased positions by around 5,280,196 shares, while 23 investors held positions by with 23,210,502 shares. The mentioned changes placed institutional holdings at 30,582,069 shares, according to the latest SEC report filing. CDLX stock had 26 new institutional investments in for a total of 567,955 shares, while 32 institutional investors sold positions of 770,001 shares during the same period.